Literature DB >> 1404121

Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity.

J G Brun1, H J Haga, E Bøe, I Kallay, C Lekven, H B Berntzen, M K Fagerhol.   

Abstract

Calprotectin (L1) is a major granulocyte and monocyte protein which is released during activation of these cells. The plasma level of L1 is thought to reflect disease activity in rheumatoid arthritis (RA). In our cross sectional study of 70 patients with RA, L1 had significant correlations with erythrocyte sedimentation rate (r = 0.50), C-reactive protein (r = 0.58), orosomucoid (r = 0.62), platelet count (r = 0.42), leukocyte count (r = 0.33) and IgM rheumatoid factor (r = 0.32); and with the following clinical variables: number of swollen joints (r = 0.24), grip strength (r = -0.22), PIP joint circumferences (r = 0.33) and a combined global assessment score (r = 0.24). L1 was higher in seropositive (median 14,861 micrograms/l) than seronegative patients (median 10,487 micrograms/l) (p less than 0.03).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404121

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

1.  Structure of calcium-bound human S100A13 at pH 7.5 at 1.8 A resolution.

Authors:  Fabiana Lica Imai; Koji Nagata; Naoto Yonezawa; Minoru Nakano; Masaru Tanokura
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-01-31

2.  Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.

Authors:  Jana Hurnakova; Hana Hulejova; Jakub Zavada; Martin Komarc; Lucie Andres Cerezo; Herman Mann; Jiri Vencovsky; Karel Pavelka; Ladislav Senolt
Journal:  Clin Rheumatol       Date:  2018-04-14       Impact factor: 2.980

Review 3.  Functional and clinical aspects of the myelomonocyte protein calprotectin.

Authors:  B Johne; M K Fagerhol; T Lyberg; H Prydz; P Brandtzaeg; C F Naess-Andresen; I Dale
Journal:  Mol Pathol       Date:  1997-06

Review 4.  Calprotectin in rheumatic diseases.

Authors:  Francesca Ometto; Lara Friso; Davide Astorri; Costantino Botsios; Bernd Raffeiner; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-01

5.  Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein.

Authors:  Yanping Wang; Ying Liang
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

6.  Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.

Authors:  Hilde Berner Hammer; Sigrid Odegard; Magne K Fagerhol; Robert Landewé; Désirée van der Heijde; Till Uhlig; Petter Mowinckel; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

7.  S100A8 and S100A9 inhibit neutrophil oxidative metabolism in-vitro: involvement of adenosine metabolites.

Authors:  Herve Y Sroussi; Yu Lu; Qin L Zhang; Dana Villines; Phillip T Marucha
Journal:  Free Radic Res       Date:  2010-04

8.  Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.

Authors:  Lucie Andrés Cerezo; Heřman Mann; Ondřej Pecha; Lenka Pleštilová; Karel Pavelka; Jiří Vencovský; Ladislav Senolt
Journal:  Arthritis Res Ther       Date:  2011-07-26       Impact factor: 5.156

9.  Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator.

Authors:  Sam Tirkos; Susan Newbigging; Van Nguyen; Mary Keet; Cameron Ackerley; Geraldine Kent; Richard F Rozmahel
Journal:  Respir Res       Date:  2006-03-29

10.  Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis.

Authors:  Yueh-Sheng Chen; Weixing Yan; Carolyn L Geczy; Matthew A Brown; Ranjeny Thomas
Journal:  Arthritis Res Ther       Date:  2009-03-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.